X-COR Therapeutics, an Allston, MA-based developer of a novel extracorporeal carbon dioxide removal device, closed a $2.6M seed financing.
Alira Health’s investment arm, Alira Health Ventures, led the financing with syndication from Good Growth Capital, PiSA Biopharm, Flybridge Partners’ Graduate Syndicate, and other notable angel investors.
The company intends to use the funds to continue developing its device toward clinical trials.
Led by Jayon Wang, CEO, X-COR is a medical device company creating a carbon dioxide removal device that uses ultra-low-blood flows for the treatment for acute respiratory failure. Its novel technology is a patent-pending medical device and accompanying control algorithm that enables physicians to directly remove excess carbon dioxide from lung failure patients.
FinSMEs
12/11/2020